| Autor: |
Broadwater D; Department of Biochemistry and Molecular Biology, Michigan State University, East Lansing, Michigan 48824, USA., Medeiros HCD; Department of Biochemistry and Molecular Biology, Michigan State University, East Lansing, Michigan 48824, USA., Lunt RR; Department of Chemical Engineering and Materials Science, Michigan State University, East Lansing, Michigan 48824, USA; email: sophia@msu.edu, rlunt@msu.edu.; Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA., Lunt SY; Department of Biochemistry and Molecular Biology, Michigan State University, East Lansing, Michigan 48824, USA.; Department of Chemical Engineering and Materials Science, Michigan State University, East Lansing, Michigan 48824, USA; email: sophia@msu.edu, rlunt@msu.edu. |
| Abstrakt: |
Photoactive agents are promising complements for both early diagnosis and targeted treatment of cancer. The dual combination of diagnostics and therapeutics is known as theranostics. Photoactive theranostic agents are activated by a specific wavelength of light and emit another wavelength, which can be detected for imaging tumors, used to generate reactive oxygen species for ablating tumors, or both. Photodynamic therapy (PDT) combines photosensitizer (PS) accumulation and site-directed light irradiation for simultaneous imaging diagnostics and spatially targeted therapy. Although utilized since the early 1900s, advances in the fields of cancer biology, materials science, and nanomedicine have expanded photoactive agents to modern medical treatments. In this review we summarize the origins of PDT and the subsequent generations of PSs and analyze seminal research contributions that have provided insight into rational PS design, such as photophysics, modes of cell death, tumor-targeting mechanisms, and light dosing regimens. We highlight optimizable parameters that, with further exploration, can expand clinical applications of photoactive agents to revolutionize cancer diagnostics and treatment. |
